ReviewJournal of diabetes research2016
Antidiabetic Effects of Resveratrol: The Way Forward in Its Clinical Utility.
Review in Journal of diabetes research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 1 synthesis or guideline pooled it, 100 citations in OpenAlex.
- Influence of Age and Dose on the Effect of Resveratrol for Glycemic Control in Type 2 Diabetes Mellitus: Systematic Review and Meta-Analysis.Molecules (Basel, Switzerland) · 2022Pooled it
- Effect of Resveratrol on Markers of Oxidative Stress and Sirtuin 1 in Elderly Adults with Type 2 Diabetes.International journal of molecular sciences · 2023Trial
- Efficacy and Safety of Resveratrol in Type 1 Diabetes Patients: A Two-Month Preliminary Exploratory Trial.Nutrients · 2020Trial
- Resveratrol for Cancer Radio-Sensitization: Ready for Prime Time or Future Perspective.Food science & nutrition · 2026Review
- Network Pharmacology and Transcriptome Analysis Reveal Potential Cardiometabolic Targets ofBiomedicines · 2026Article
- Current Understanding of Bovine Ketosis: From Molecular Basis to Farm-Level Management.Animals : an open access journal from MDPI · 2025Review
- Natural Antidiabetic Agents: Insights into Ericaceae-Derived Phenolics and Their Role in Metabolic and Oxidative Modulation in Diabetes.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Deciphering the biophysical aspects of the interaction of 3,5,4'-trihydroxy-trans-stilbene with ribonuclease A: spectroscopic and computational studies.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Modern Approaches to Diabetes: The Role of Phytochemicals in Targeting Molecular Receptors.Current topics in medicinal chemistry · 2025Review
- Inhibition of Human Salivary and Pancreatic α-Amylase by Resveratrol Oligomers.Journal of medicinal chemistry · 2024Article
- Lingonberry (Nutrients · 2024Article
- The Role of NRF2 in Trinucleotide Repeat Expansion Disorders.Antioxidants (Basel, Switzerland) · 2024Review
- Promising Phytoconstituents in Diabetes-related Wounds: Mechanistic Insights and Implications.Current diabetes reviews · 2024Review
- The Role of Resveratrol in Aging and Senescence: A Focus on Molecular Mechanisms.Current molecular medicine · 2024Review
- Resveratrol and Gut Microbiota Synergy: Preventive and Therapeutic Effects.International journal of molecular sciences · 2023Review
- A comprehensive review of the effects of resveratrol on glucose metabolism: unveiling the molecular pathways and therapeutic potential in diabetes management.Molecular biology reports · 2023Review
- An Overview on Plant Derived Phenolic Compounds and Their Role in Treatment and Management of Diabetes.Journal of pharmacopuncture · 2022Review
- Resveratrol Inhibits Metabolism and Affects Blood Platelet Function in Type 2 Diabetes.Nutrients · 2022Article
- Resveratrol Inhibited ADAM10 Mediated CXCL16-Cleavage and T-Cells Recruitment to Pancreatic β-Cells in Type 1 Diabetes Mellitus in Mice.Pharmaceutics · 2022Article
- Dietary Polyphenols and Their Role in Oxidative Stress-Induced Human Diseases: Insights Into Protective Effects, Antioxidant Potentials and Mechanism(s) of Action.Frontiers in pharmacology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite recent advances in the understanding and management of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.